指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

成人铜绿假单胞菌下呼吸道感染管理中国专家共识(2022年版)

[Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2022-01-01
一句话结论中华医学会呼吸病学分会感染学组更新共识:铜绿假单胞菌下呼吸道感染应区分感染与定植,按病情轻重、耐药风险和经验/目标治疗原则选药,重症或多重耐药风险者联合两类可能敏感药物。

铜绿假单胞菌(PA)是我国医院获得性肺炎(HAP)第二常见革兰阴性菌(16.9%-22.0%),社区获得性肺炎(CAP)中约占1.0%,重症CAP中升至1.8%-8.3%;有PA感染史、支气管扩张、极重度COPD或气管切开者CAP中PA占67.0%。中华医学会呼吸病学分会感染学组在2014年版基础上更新本共识,聚焦病原检测、诊断、抗菌治疗、综合管理和感染防控。共识明确慢性下呼吸道感染的诊断需综合评估基础结构性肺病、临床表现及1年内≥2次(间隔至少3个月)合格下呼吸道标本检出PA,并强调区分感染与定植。

要点

  • 有PA感染史、支气管扩张、极重度COPD或气管切开者,CAP中PA占67.0%,经验治疗需覆盖PA。
  • 慢性PA下呼吸道感染诊断需:基础结构性肺病或免疫受损、有下呼吸道感染表现、1年内≥2次(间隔至少3个月)合格标本检出PA。
  • 重症或有多重耐药PA风险者,经验治疗用两类不同类别、均可能敏感的抗菌药物联合;非重症疑似PA肺炎选肺浓度高的单药。
  • 碳青霉烯耐药PA或难治性耐药PA下呼吸道感染,体外敏感的新型酶抑制剂复方制剂(如头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦、亚胺培南/西司他丁/雷利巴坦)推荐作为一线选择,头孢地尔可作为二线。
  • 不推荐全身和局部预防性使用抗菌药物;除标准预防外,推荐隔离和预防接触传播以阻断PA传播。

适用人群与场景

  • 成人铜绿假单胞菌下呼吸道感染患者,包括急性下呼吸道感染(社区获得性肺炎、医院获得性肺炎、呼吸机相关性肺炎、气管支气管炎、肺脓肿和脓胸)和慢性下呼吸道感染。
  • 有PA感染史、支气管扩张、极重度COPD或气管切开病史的CAP患者,PA占比高(67.0%)。
  • 病情危重或存在PA感染高危因素、疑诊PA肺炎的患者。
  • 有基础慢性结构性肺病(如支气管扩张、囊性纤维化、COPD)或免疫受损状态的患者。

诊断标准与关键阈值

  • 慢性PA下呼吸道感染诊断需综合评估:(1)基础慢性结构性肺病,如支气管扩张、囊性纤维化、COPD,或免疫受损状态;(2)存在下呼吸道感染临床表现;(3)1年内≥2次(间隔至少3个月)合格下呼吸道标本检出PA。
  • 从下呼吸道标本分离出PA时,需注意区分感染与定植。
  • 药敏试验是PA耐药检测的常规方法,并作为目标治疗依据;当药敏显示现有药物活性有限时,建议联合药敏试验选择体外有相加或协同作用的抗菌药物用于联合治疗。
  • 如条件允许,推荐对PA分离株进行耐药机制的快速检测,如碳青霉烯酶表型确证试验;不推荐常规检测耐药基因来选择治疗药物。

处置流程与药物剂量

  • 危重或存在PA感染高危因素的急性下呼吸道感染患者,应在采集微生物检测标本后启动覆盖PA的经验性抗菌治疗。
  • 疑似PA肺炎但非危重患者,经验治疗选择肺浓度高的单种抗PA活性抗菌药物。
  • 脓毒症等严重病情或存在多重耐药PA风险因素者,经验治疗使用两类不同类别、均可能敏感的抗菌药物联合。
  • 抗菌方案应遵循药代动力学/药效学原则,确保足够剂量和给药频次。
  • 确诊PA下呼吸道感染后,根据药敏结果选择抗菌药物;无显著基础疾病者推荐肺浓度足够的活性抗菌药物单药治疗而非联合治疗;当所有可用活性药物肺内浓度均差时,联合治疗是必须的。
  • 碳青霉烯耐药PA(CRPA)或难治性耐药PA(DTR-PA)引起的下呼吸道感染,若新型酶抑制剂复方制剂(如头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦、亚胺培南/西司他丁/雷利巴坦)体外敏感,推荐作为一线选择;头孢地尔可作为二线治疗;也可考虑以多黏菌素为基础的联合治疗。
  • 耐药PA下呼吸道感染的其他可能有效策略包括β-内酰胺类延长输注时间、联合治疗和吸入抗菌药物治疗。
  • 有基础慢性结构性肺病者,抗菌方案(药物、剂量、给药途径和疗程)应根据临床特征、药敏结果和治疗目标(控制急性加重症状、清除新出现的PA或预防频繁急性加重患者的发作)决定。

红旗征与不能漏的情况

  • 脓毒症等严重病情:经验治疗需联合两类不同类别、均可能敏感的抗菌药物。
  • 存在多重耐药PA风险因素:经验治疗需联合两类不同类别、均可能敏感的抗菌药物。
  • 碳青霉烯耐药PA或难治性耐药PA:需按新型酶抑制剂复方制剂体外敏感性选择一线或二线方案。

研究设计与关键结果

  • 中华医学会呼吸病学分会感染学组在2014年版共识基础上更新,聚焦病原检测、诊断、抗菌治疗、综合管理和感染预防与控制。
  • PA是我国HAP第二常见革兰阴性菌(16.9%-22.0%);CAP中PA比例约1.0%,重症CAP中升至1.8%-8.3%;有PA感染史、支气管扩张、极重度COPD或气管切开者CAP中PA占67.0%。

证据类型、等级与局限

  • 证据类型:专家共识(中华医学会呼吸病学分会感染学组更新)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对危重或存在PA感染高危因素的急性下呼吸道感染患者,应在留取微生物标本后经验性覆盖PA,避免延误。
  • 非危重疑似PA肺炎选肺浓度高的单药;脓毒症或有多重耐药PA风险者用两类可能敏感药物联合。
  • 确诊PA后按药敏选药;无显著基础疾病者用肺浓度足够的单药而非联合;所有活性药物肺内浓度均差时联合治疗是必须的。
  • CRPA或DTR-PA若新型酶抑制剂复方制剂体外敏感,推荐作为一线;头孢地尔可作为二线;也可考虑多黏菌素为基础联合。
  • 有基础慢性结构性肺病者,抗菌方案按临床特征、药敏和治疗目标个体化决定。
  • 除标准预防外,推荐隔离和预防接触传播;不推荐全身和局部预防性使用抗菌药物。

指南或共识出处

  • 《铜绿假单胞菌下呼吸道感染诊治专家共识(2014年版)》
  • 《成人铜绿假单胞菌下呼吸道感染管理中国专家共识(2022年版)》,中华医学会呼吸病学分会感染学组

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Pseudomonas aeruginosa (PA) is the second common Gram-negative bacterium for hospital acquired pneumonia (HAP) in China (16.9%-22.0%). The proportion of PA in community acquired pneumonia (CAP) was about 1.0%, while increased to 1.8%-8.3% in severe CAP. PA accounted for 67.0% of CAP in patients with a history of PA infection, bronchiectasis, very severe chronic obstructive pulmonary disease (COPD) or tracheotomy. Considering the high disease burden of lower respiratory tract infections (LRTIs) caused by PA, together with the progress in this field in recent years, the Pulmonary Infection Assembly of Chinese Thoracic Society updated the "Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults (2014 version)", focusing on pathogen detection, diagnosis, antimicrobial therapy, comprehensive management, infection prevention and control.PA causes both acute and chronic LTRIs. Acute LRTIs mainly include pneumonia (CAP, HAP and ventilator-associated pneumonia), tracheobronchitis, lung abscess and empyema. The diagnosis of chronic LTRIs should be based on a comprehensive assessment of (1) underlying chronic structural lung diseases, such as bronchiectasis, cystic fibrosis, COPD, or immunocompromised conditions; (2) the presence of clinical manifestations of LRTIs; and (3) ≥ two times (at least 3 months apart) of PA detected from eligible lower respiratory tract specimens within 1 year. It is important to distinguish infection from colonization when PA is isolated from lower respiratory tract specimens. Drug susceptibility test is a conventional method for PA resistance detection and serves as a basis for target therapy. When drug susceptibility test shows limited activity of available agents, combined susceptibility test is suggested to select antimicrobial drugs with additive or synergistic effect in vitro for combination therapy. Rapid test of resistance mechanisms of PA isolates, such as carbapenemase phenotype confirmation tests, is recommended if available. It is recommended not to routinely detect resistance genes for choosing therapeutic agents.For patients with acute LRTIs in critical condition or with high risk factors for PA infection, empirical antimicrobial therapy covering PA should be initiated after collecting specimens for microbiological tests. In patients with suspected PA pneumonia who are not critically ill, single antimicrobial drug of anti-PA activity with high lung concentration should be selected for empirical treatment. However, for patients with a serious condition such as sepsis or with risk factors for multidrug-resistant (MDR) PA, a combination of two different classes of antimicrobial drugs that are both potentially susceptible should be used. The antimicrobial regimen should follow pharmacokinetics/pharmacodynamics principles to ensure adequate dosage and administration frequency. For confirmed PA LRTIs, antibiotics should be selected based on drug sensitivity. In patients without significant underlying diseases, single therapy of an active antimicrobial with adequate pulmonary concentration is recommended rather than combination therapy; when all the available active agents have poor intrapulmonary concentrations, combination therapy is obligatory. For LRTIs caused by carbapenem-resistant PA (CRPA) or difficult-to-treat resistance PA (DTR-PA), if an agent of new enzyme inhibitor, such as ceftolozane/tazobactam, ceftazidime/avibactam, and imipenem/cilastatin/relebactam shows in vitro sensitivity, it is recommended as the first-line choice; cefiderocol may serve as the second-line treatment. Combination therapy based on polymyxins may also be considered. Other potentially successful approaches for drug-resistant PA LRTIs include extended infusion time of β-lactams, combination therapy and inhaled antimicrobial therapy.In patients with underlying chronic structural lung diseases, the antimicrobial regimen (drug, dosage, route of administration, and duration of therapy) should be decided according to clinical features, drug sensitivity, and treatment goals (control of exacerbated symptoms, eradication of new-emerging PA, or prevention of flare-ups in patients with frequent exacerbation).Along with antimicrobial therapy, comprehensive care including airway clearance therapy (ACT), oxygen therapy, nutritional support and organ function protection should be provided. From the perspective of nosocomial infection prevention and control, isolation and prophylaxis of contact transmission are recommended to block PA transmission in addition to standard prevention measures. Targeted active screening, timely monitoring and feedback can help the prevention and control of MDR-PA. The systemic and topical use of prophylactic antimicrobials is not recommended.

铜绿假单胞菌是难治性下呼吸道感染最常见致病菌之一,由于其耐药严重和易形成生物被膜,特别是近10多年来碳青霉烯类耐药株的出现,使其治疗更为困难;同时新的治疗药物和治疗策略不断问世,有必要加以评估以指导临床合理应用。中华医学会呼吸病学分会感染学组在《铜绿假单胞菌下呼吸道感染诊治专家共识(2014年版)》的基础上进行更新,并以临床诊治和预防的思路和技术为重点,以期为临床医生规范化诊治铜绿假单胞菌下呼吸道感染提供切实可行的参考。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

参考来源

  1. [Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)]. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35927044. doi:10.3760/cma.j.cn112147-20220407-00290

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。